Qrons Inc. Overview
Pro stress-test →Qrons Inc., headquartered in New York City with research centered in Israel, develops products, treatments and technologies to combat neuronal and infectious diseases, engaging in strategic arrangements with companies, universities and scientists developing breakthroughs in stem cells, antibiotic resistant drug development and tissue engineering. The company focuses on combatting traumatic brain injuries and other neuronal diseases alongside work on infectious disease and sepsis.
Strategic Profile
Pro stress-test →Qrons has two product candidates for treating TBIs: QS100™, a 3D printable implantable MSCs-synthetic hydrogel for penetrating brain injuries, and QS200™, an injectable MSCs-synthetic hydrogel for diffused injuries commonly referred to as concussions. The company leverages artificial intelligence, machine learning, and proprietary tissue engineering technologies to address high-impact neurological conditions with significant commercial potential.
Competitive Landscape
Pro stress-test →Qrons competes in preclinical and early-stage clinical biotechnology for traumatic brain injury and neuronal disease treatment. Direct competitors in cell-based TBI therapeutics are limited, though broader neurological biotech includes companies like Neuralstem, BioDelivery Sciences, and Passage Bio. The infectious disease focus (antibiotic resistance) positions the company against larger therapeutics players. Differentiation stems from proprietary synthetic hydrogel platforms and Israeli research partnerships.
Industry Context
Qrons Inc. operates in Cell-based regenerative medicine for neurological injury.
Key facts
Founded: 1998 · Headquarters: New York, US · Employees: 11-50 · Revenue: N/A · Market cap: N/A